-
Will Merck Settle Some of the Vioxx Cases, or Is This True Hardball?
Can Merck’s Lawyers Defend Against Each of the Thousands of Vioxx Cases? Alex Berenson, of the New York Times ("NYT"), reported that in an August 25, 2005 interview Merck’s general counsel Kenneth C. Frazier…
-
Drug Companies Object to Early Warnings on New FDA “Drug Watch” Site
Will the FDA be Steadfast in Showdown with Big Pharma Over Drug Watch Plan? The FDA intends to post emerging drug-safety concerns that are being evaluated by the agency on a new "Drug Watch"…
-
Vioxx: Merck Has No Plans for a Global Settlement Says General Counsel Frazier
Merck Will Continue to Fight Each Vioxx Lawsuit, Including Humeston Case in NJ Merck & Co.’s General Counsel Kenneth Frazier reiterated in the first part of September 2005 that Merck has no interest in…
-
Propulsid: Blockbuster Drug With Danger Signals That Were Ignored
FDA’s Failure to Act in 1998 Foreshadowed Its Later Mishandling of Vioxx and Bextra A June 2005 article in The New York Times ("NYT") by Gardiner Harris and Eric Koli provided insight about how…
-
FDA Mandates “iPLEDGE” Accutane Registry in Effort to Prevent Birth Defects
Patients Must Register by December 31, 2005 to Get Accutane Re-fills In mid-August 2005 the FDA mandated that all patients who uses the acne drug Accutane will have to enroll in a national Accutane…
-
Serzone MDL Class Action Settlement Approved by Federal Court Judge Godwin
More Than 2500 Potential Claimants, However, "Opt-out" of This Serzone Settlement United States District Court Judge Joseph R. Godwin, on September 2, 2005, gave final court approval to a $70 million settlement of Serzone…
